-
NMPA Announcement on Issuing the Provisions for the Supervision and Administration of Children's Cosmetics
2021-10-08
The National Medical Products Administration has organized to formulate the Provisions for the Supervision and Administration of Children's Cosmetics, which was issued on October 8. The issues related to the implementation of the Provisions are hereby announced as follows.
-
NPMA Announcement on Implementing the Application with Electronic Common Technical Documents
2021-09-30
The National Medical Products Administration comprehensively carried out and promoted the application with electronic common technical document (eCTD). The relevant issues related to eCTD application are hereby announced as follows.
-
NMPA Announcement on Matters Concerning the Implementation of the Provisions for Medical Device Registration and Filing and the Provisions for In-vitro Diagnostic Reagent Registration and Filing
2021-09-29
The Provisions for Medical Device Registration and Filing (SAMR Decree No.47) and the Provisions for In-vitro Diagnostic Reagent Registration and Filing (SAMR Decree No.48) were issued and implemented as of October 1, 2021.
-
NMPA Announcement on Adding the Medication Information for Children to the Package Insert of Cisplatin injections and Other Varieties
2021-09-29
In order to better meet the clinical medication needs of children, upon the study and demonstration, the package inserts of Cisplatin injections and other varieties may be added with the children users and dosage and usage for children according to the requirements.
-
NMPA Announcement on Issuing the List of Medical and Pharmaceutical Journals Approved to Advertise Prescription Drugs
2021-08-27
The Journal of Alzheimer's Disease and Related Diseases is approved to be included in the list of medical and pharmaceutical journals approved to advertise prescription drugs.
-
NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs (Forty-three Batch)
2021-07-23
On July 22, the Catalogue of Reference Preparations of Generic Drugs (Fortythree Batch) was issued, upon review and determination by the NMPA Experts Committee of Quality and Efficacy Consistency Evaluation of Generic Drugs.